Diagnostic and prognostic value of deregulated long non-coding RNA RPPH1 in patients with severe community-acquired pneumonia: a retrospective cohort study
Tóm tắt
Severe community-acquired pneumonia (SCAP) is one of the most common critical and acute diseases in the respiratory and acute medicine department. The expression and significance of lncRNA RPPH1 (RPPH1) in SCAP were assessed aiming to explore a biomarker assisting in the screening and management of SCAP. This study is a retrospective study enrolled 97 SCAP patients, 102 mild community-acquired pneumonia (MCAP) patients, and 65 healthy individuals. The serum expression of RPPH1 of study subjects was evaluated using PCR. The diagnostic and prognostic significance of RPPH1 in SCAP was evaluated by ROC and Cox analyses. Meanwhile, the correlation of RPPH1 with patients’ clinicopathological features was evaluated by spearman correlation analysis to evaluate its role in assessing disease severity. A significant downregulation of RPPH1 was observed in the serum of SCAP patients compared with MCAP and healthy individuals. RPPH1 was positively correlated with ALB (r = 0.74) and negatively correlated with C-reactive protein (r = -0.69), neutrophil-to-lymphocyte ratio (r = -0.88), procalcitonin (r = -0.74), and neutrophil (r = -0.84) of SCAP patients, which are associated with the development and severity of SCAP. Additionally, reduced RPPH1 was closely associated with the 28-day development-free survival of SCAP patients and served as an adverse prognostic indicator together with procalcitonin. Downregulated RPPH1 in SCAP could act as a diagnostic biomarker screening SCAP from healthy and MCAP individuals and act as a prognostic biomarker predicting patients’ disease conditions and outcomes. The demonstrated significance of RPPH1 in SCAP could assist the clinical antibiotic therapies of SCAP patients.
Tài liệu tham khảo
Mandell LA. Community-acquired pneumonia: an overview. Postgrad Med. 2015;127(6):607–15.
Bébéar C, Pereyre S, Peuchant O. Mycoplasma pneumoniae: susceptibility and resistance to antibiotics. Future Microbiol. 2011;6(4):423–31.
Esposito S, Argentiero A, Gramegna A, Principi N. Mycoplasma pneumoniae: a pathogen with unsolved therapeutic problems. Expert Opin Pharmacother. 2021;22(9):1193–202.
Jiang J, Hu C, Li Y, Pan P, Su X, Deng P, et al. Transmission electron microscopy improves the diagnostic sensitivity in nonbacterial etiology of severe pneumonia: a retrospective study. Am J Med Sci. 2019;357(4):289–95.
Kaziani K, Sotiriou A, Dimopoulos G. Duration of pneumonia therapy and the role of biomarkers. Curr Opin Infect Dis. 2017;30(2):221–5.
Montull B, Menendez R, Torres A, Reyes S, Mendez R, Zalacain R, et al. Predictors of severe sepsis among patients hospitalized for community-acquired pneumonia. PLoS ONE. 2016;11(1):e0145929.
Opal SM, Wittebole X. Biomarkers of infection and sepsis. Crit Care Clin. 2020;36(1):11–22.
Huang S, Feng C, Chen L, Huang Z, Zhou X, Li B, et al. Identification of potential key long non-coding RNAs and target genes associated with pneumonia using long non-coding RNA sequencing (lncRNA-Seq): a preliminary study. Med Sci Monit. 2016;22:3394–408.
Yue K, Ma JL, Jiang T, Yue J, Sun SK, Shen JL, et al. LncRNA RPPH1 predicts poor prognosis and regulates cell proliferation and migration by repressing P21 expression in gastric cancer. Eur Rev Med Pharmacol Sci. 2020;24(21):11072–80.
Liang ZX, Liu HS, Wang FW, Xiong L, Zhou C, Hu T, et al. LncRNA RPPH1 promotes colorectal cancer metastasis by interacting with TUBB3 and by promoting exosomes-mediated macrophage M2 polarization. Cell Death Dis. 2019;10(11):829.
Cao B, Huang Y, She DY, Cheng QJ, Fan H, Tian XL, et al. Diagnosis and treatment of community-acquired pneumonia in adults: 2016 clinical practice guidelines by the Chinese Thoracic Society Chinese Medical Association. Clin Respir J. 2018;12(4):1320–60.
Kolditz M, Braeken D, Ewig S, Rohde G. Severity assessment and the immediate and long-term prognosis in community-acquired pneumonia. Semin Respir Crit Care Med. 2016;37(6):886–96.
Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58(5):377–82.
Florin TA, Ambroggio L, Brokamp C, Zhang Y, Rattan M, Crotty E, et al. Biomarkers and Disease Severity in Children With Community-Acquired Pneumonia. Pediatrics. 2020;145(6):e20193728.
Neuhaus T, Ewig S. Defining severe community-acquired pneumonia. Med Clin North Am. 2001;85(6):1413–25.
Gu R, Wang L, Tang M, Li SR, Liu R, Hu X. LncRNA Rpph1 protects amyloid-β induced neuronal injury in SK-N-SH cells via miR-122/Wnt1 axis. Int J Neurosci. 2020;130(5):443–53.
Wu Y, Cheng K, Liang W, Wang X. lncRNA RPPH1 promotes non-small cell lung cancer progression through the miR-326/WNT2B axis. Oncol Lett. 2020;20(4):105.
Povoa P, Martin-Loeches I, Ramirez P, Bos LD, Esperatti M, Silvestre J, et al. Biomarkers kinetics in the assessment of ventilator-associated pneumonia response to antibiotics - results from the BioVAP study. J Crit Care. 2017;41:91–7.
Zhydkov A, Christ-Crain M, Thomann R, Hoess C, Henzen C, Werner Z, et al. Utility of procalcitonin, C-reactive protein and white blood cells alone and in combination for the prediction of clinical outcomes in community-acquired pneumonia. Clin Chem Lab Med. 2015;53(4):559–66.
Rozga J, Piatek T, Malkowski P. Human albumin: old, new, and emerging applications. Ann Transplant. 2013;18:205–17.
Oh TK, Song IA, Lee JH. Clinical usefulness of C-reactive protein to albumin ratio in predicting 30-day mortality in critically ill patients: A retrospective analysis. Sci Rep. 2018;8(1):14977.
Zhang HF, Ge YL, Wang HY, Zhang Q, Li WQ, Chen Y, et al. Neutrophil-to-Lymphocyte ratio improves the accuracy and sensitivity of pneumonia severity index in predicting 30-day mortality of CAP Patients. Clin Lab. 2019;65(10).
Ge YL, Zhang HF, Zhang Q, Zhu XY, Liu CH, Wang N, et al. Neutrophil-to-Lymphocyte ratio in adult community-acquired pneumonia patients correlates with unfavorable clinical outcomes. Clin Lab. 2019;65(5).
Kruger S, Ewig S, Marre R, Papassotiriou J, Richter K, von Baum H, et al. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes. Eur Respir J. 2008;31(2):349–55.
Huang DT, Yealy DM, Filbin MR, Brown AM, Chang CH, Doi Y, et al. Procalcitonin-guided use of antibiotics for lower respiratory tract infection. N Engl J Med. 2018;379(3):236–49.
D’Arrigo G, Roumeliotis S, Torino C, Tripepi G. Sample size calculation of clinical trials in geriatric medicine. Aging Clin Exp Res. 2021;33(5):1209–12.
Kang H. Sample size determination and power analysis using the G*Power software. J Educ Eval Health Prof. 2021;18:17.
Schmidt SAJ, Lo S, Hollestein LM. Research techniques made simple: sample size estimation and power calculation. J Invest Dermatol. 2018;138(8):1678–82.
Chahin A, Opal SM. Severe pneumonia caused by legionella Pneumophila: differential diagnosis and therapeutic considerations. Infect Dis Clin North Am. 2017;31(1):111–21.
Cillóniz C, Torres A, Niederman M, van der Eerden M, Chalmers J, Welte T, et al. Community-acquired pneumonia related to intracellular pathogens. Intensive Care Med. 2016;42(9):1374–86.
Tran Quang K, Tran Do H, Pham Hung V, Nguyen VuT, Tran Xuan B, Larsson M, et al. Study on the co-infection of children with severe community-acquired pneumonia. Pediatr Int. 2022;64(1):e14853.
Wesołowski A, Targowski T. Community-acquired pneumonia caused by biological pathogens. Pol Merkur Lekarski. 2012;33(197):248–51.
Martin-Loeches I, Garduno A, Povoa P, Nseir S. Choosing antibiotic therapy for severe community-acquired pneumonia. Curr Opin Infect Dis. 2022;35(2):133–9.
Wongsurakiat P, Chitwarakorn N. Severe community-acquired pneumonia in general medical wards: outcomes and impact of initial antibiotic selection. BMC Pulm Med. 2019;19(1):179.
Bender MT, Niederman MS. Principles of antibiotic management of community-acquired pneumonia. Semin Respir Crit Care Med. 2016;37(6):905–12.